Catalog No.
PAV02801
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Palivizumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Synagis.
Specificity
The product is specific for Palivizumab. This antibody serves as an excellent positive control for Palivizumab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 188039-54-5
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Palivizumab is a monoclonal antibody to the RSV F protein that inhibits binding of the virus to cellular receptors. When administered preseasonally to high-risk infants, palivizumab reduces the rate and severity of RSV infections and the incidence of RSV bronchiolitis. Antibodysystem Anti-Palivizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Palivizumab.
Respiratory Syncytial Virus: A Narrative Review of Updates and Recent Advances in Epidemiology, Pathogenesis, Diagnosis, Management and Prevention., PMID:40507642
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama., PMID:40458968
Respiratory syncytial virus preventives for children in Australia: current landscape and future directions., PMID:40413643
The influence of respiratory syncytial virus immunoprophylaxis on allergic sensitisation in children with respiratory allergy., PMID:40360322
Direct Out-of-Pocket Costs of Nirsevimab vs. Palivizumab during the First Respiratory Syncytial Virus Season: A Comparative Analysis., PMID:40343422
Knowledge, attitudes, and practices of Croatian pediatricians and pediatrics residents about RSV infection., PMID:40328920
Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants., PMID:40317387
Human iPS cell-derived respiratory organoids as a model for respiratory syncytial virus infection., PMID:40262853
Summary of the National Advisory Committee on Immunization (NACI) Statement on the Prevention of Respiratory Syncytial Virus (RSV) in Infants., PMID:40241712
Optimizing risk factors to guide COST-effective use of palivizumab in KOREAN infants., PMID:40214194
Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study., PMID:40211817
Health economic evaluation of implementing a universal immunization program with nirsevimab compared to standard of care for the prevention of respiratory syncytial virus disease in Canadian infants., PMID:40186452
RSV Prevention Strategies in Korean Children: A Review of Current Approaches and Emerging Options., PMID:40183652
Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children., PMID:40111069
Respiratory Syncytial Virus Burden in Premature Infants: The Role of Season With and Without RSV Immunoprophylaxis in a Multicenter Study., PMID:40042149
Recommendation for immune prophylaxis of respiratory syncytial virus infection in children., PMID:40032543
Cost-effectiveness of wastewater and environmental monitoring of respiratory syncytial virus to guide universal infant immunoprophylaxis in Canada., PMID:40019444
Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants., PMID:40006718
Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review., PMID:40006706
Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada., PMID:39984979
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection., PMID:39976899
Practice recommendations for respiratory syncytial virus prophylaxis among children in Hong Kong., PMID:39957107
Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection., PMID:39905524
Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations., PMID:39900111
Efficacy of a standardized regional palivizumab administration protocol based on epidemic prediction for the following season., PMID:39892510
An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling., PMID:39828098
Investigating the metabolic load of monoclonal antibody production conveyed to an inducible CHO cell line using a transfer-rate online monitoring system., PMID:39828082
Inpatient service utilization amongst infants diagnosed with Respiratory Syncytial Virus infection (RSV) in the United States., PMID:39804848
The recent landscape of RSV vaccine research., PMID:39802673
Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab., PMID:39788540
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options., PMID:39771979
[Benefits of home-based administration of palivizumab in high-risk groups]., PMID:39760599
Evolving Strategies for Respiratory Syncytial Virus (RSV): A Review Article of Preventive Agents and Vaccines for RSV., PMID:39744803
The molecular epidemiology of respiratory syncytial virus in Ontario, Canada from 2022-2024 using a custom whole genome sequencing assay and analytics package., PMID:39721564
Amino acid substitutions in the fusion protein of respiratory syncytial virus in Fukushima, Japan during 2008-2023 and their effects., PMID:39719011
Risks and prevention of severe respiratory syncytial virus infection among infants and children with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, inborn errors of metabolism, or neuromuscular diseases in Japan., PMID:39674346
Trends in endemic of respiratory syncytial virus infection during COVID-19 pandemic and difficulty in obtaining optimal timing of palivizumab prophylaxis., PMID:39667557
Approach to prevention of respiratory syncytial virus disease in infants by passive immunization., PMID:39638376
Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue., PMID:39575302
A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein., PMID:39572535
Impact of Palivizumab in Preventing Severe Acute Lower Respiratory Infection in Moderate-to-Late Preterm Infants: A Nationwide Cohort Study., PMID:39536788
Nationwide Epidemiology and Outpatient Healthcare Resource Use of Children with Respiratory Syncytial Virus from 2005 to 2021., PMID:39506567
Impact of respiratory tract infections on spinal muscular atrophy with focus on respiratory syncytial virus infections: a single-centre cohort study., PMID:39463279
RSV prevention options for infants and older adults: A specific expanding competitive arena., PMID:39442242
Nirsevimab to reduce infant morbidity from respiratory syncytial virus., PMID:39353638
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing., PMID:39350745
Factors Associated With Hospitalization, Length of Stay, and Hospital Expenditures for Respiratory Syncytial Virus Infection in Japanese Infants and Children According to Palivizumab-indicated Underlying Conditions: The LIFE Study., PMID:39259860
Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments., PMID:39257372
The Need for RSV Prophylaxis in LMICs., PMID:39252637
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)., PMID:39241352
For research use only. Not for human or drug use.
